103 related articles for article (PubMed ID: 1461144)
1. Normal plasminogen activator inhibitor levels at long-term follow-up after jejuno-ileal bypass surgery in morbidly obese individuals.
Sylvan A; Rutegård JN; Janunger KG; Sjölund B; Nilsson TK
Metabolism; 1992 Dec; 41(12):1370-2. PubMed ID: 1461144
[TBL] [Abstract][Full Text] [Related]
2. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
Gürlek A; Bayraktar M; Kirazli S
Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
[TBL] [Abstract][Full Text] [Related]
3. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.
Lindgren A; Lindoff C; Norrving B; Astedt B; Johansson BB
Stroke; 1996 Jun; 27(6):1066-71. PubMed ID: 8650716
[TBL] [Abstract][Full Text] [Related]
4. The influence of weight loss on fibrinolytic and metabolic parameters in obese children and adolescents.
Sudi KM; Gallistl S; Tröbinger M; Payerl D; Weinhandl G; Muntean W; Aigner R; Borkenstein MH
J Pediatr Endocrinol Metab; 2001 Jan; 14(1):85-94. PubMed ID: 11220710
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effect of a moderately energy-restricted diet on fibrinolytic factors in non-obese men.
Velthuis-te Wierik EJ; Meijer P; Kluft C; van den Berg H
Metabolism; 1995 Dec; 44(12):1548-52. PubMed ID: 8786722
[TBL] [Abstract][Full Text] [Related]
6. Plasma plasminogen activator inhibitor-I is associated with plasma leptin irrespective of body mass index, body fat mass, and plasma insulin and metabolic parameters in premenopausal women.
De Mitrio V; De Pergola G; Vettor R; Marino R; Sciaraffia M; Pagano C; Scaraggi FA; Di Lorenzo L; Giorgino R
Metabolism; 1999 Aug; 48(8):960-4. PubMed ID: 10459558
[TBL] [Abstract][Full Text] [Related]
7. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
[TBL] [Abstract][Full Text] [Related]
8. Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein (a), and established cardiovascular risk factors in a north Swedish population.
Sundell IB; Nilsson TK; Hallmans G; Hellsten G; Dahlén GH
Atherosclerosis; 1989 Nov; 80(1):9-16. PubMed ID: 2532510
[TBL] [Abstract][Full Text] [Related]
9. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30.
Glueck CJ; Fontaine RN; Wang P; Subbiah MT; Weber K; Illig E; Streicher P; Sieve-Smith L; Tracy TM; Lang JE; McCullough P
Metabolism; 2001 Jul; 50(7):856-61. PubMed ID: 11436194
[TBL] [Abstract][Full Text] [Related]
10. Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men.
De Pergola G; De Mitrio V; Sciaraffia M; Pannacciulli N; Minenna A; Giorgino F; Petronelli M; Laudadio E; Giorgino R
Metabolism; 1997 Nov; 46(11):1287-93. PubMed ID: 9361687
[TBL] [Abstract][Full Text] [Related]
11. The effect of body build, diet and endocrine factors on the extrinsic fibrinolytic system in healthy young women.
Sundell IB; Nilsson TK; Hallmans G; Nygren C
Scand J Clin Lab Invest; 1988 Oct; 48(6):557-64. PubMed ID: 3146134
[TBL] [Abstract][Full Text] [Related]
12. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients.
Vukovich T; Proidl S; Knöbl P; Teufelsbauer H; Schnack C; Schernthaner G
Thromb Haemost; 1992 Sep; 68(3):253-6. PubMed ID: 1440487
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
[TBL] [Abstract][Full Text] [Related]
14. Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity.
Malavazos AE; Ermetici F; Cereda E; Coman C; Locati M; Morricone L; Corsi MM; Ambrosi B
Nutr Metab Cardiovasc Dis; 2008 Oct; 18(8):523-30. PubMed ID: 18083357
[TBL] [Abstract][Full Text] [Related]
15. Reduction of risk factors for cardiovascular diseases in morbid-obese patients following biliary-intestinal bypass: 3 years' follow-up.
Lubrano C; Cornoldi A; Pili M; Falcone S; Brandetti F; Fabbrini E; Ginanni-Corradini S; Eramo A; Marini M; Migliaccio S; Giancotti V; Badiali M; Falsetto N; Prossomariti G; Spera G
Int J Obes Relat Metab Disord; 2004 Dec; 28(12):1600-6. PubMed ID: 15543161
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor-1 and tissue-plasminogen activator in minority adolescents with type 2 diabetes and obesity.
Umpaichitra V; Hussain MM; Castells S
Pediatr Res; 2005 Sep; 58(3):483-7. PubMed ID: 15901895
[TBL] [Abstract][Full Text] [Related]
17. Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss.
Mavri A; Alessi MC; Bastelica D; Geel-Georgelin O; Fina F; Sentocnik JT; Stegnar M; Juhan-Vague I
Diabetologia; 2001 Nov; 44(11):2025-31. PubMed ID: 11719834
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states.
Scelles V; Raccah D; Alessi MC; Vialle JM; Juhan-Vague I; Vague P
Diabete Metab; 1992; 18(1):38-42. PubMed ID: 1563535
[TBL] [Abstract][Full Text] [Related]
19. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance.
Hadigan C; Meigs JB; Rabe J; D'Agostino RB; Wilson PW; Lipinska I; Tofler GH; Grinspoon SS;
J Clin Endocrinol Metab; 2001 Feb; 86(2):939-43. PubMed ID: 11158071
[TBL] [Abstract][Full Text] [Related]
20. Differential response of plasma plasminogen activator inhibitor 1 after weight loss surgery in patients with or without type 2 diabetes.
Mossberg KE; Pournaras DJ; Welbourn R; le Roux CW; Brogren H
Surg Obes Relat Dis; 2017 Jan; 13(1):53-57. PubMed ID: 27387691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
